Clinical Trial – A Study of Ibrutinib + Obinutuzumab – Chronic Lymphocytic Leukemia

1 Answer

Dana-Farber Cancer Institute is running a clinical trial to test drugs called Obinutuzumab and Ibrutinib to treat chronic lymphocytic leukemia. This research study is evaluating a combination of two drugs, ibrutinib and obinutuzumab, as a possible treatment for Chronic Lymphocytic Leukemia (CLL). The drugs are Obinutuzumab and Ibrutinib.
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib Study of Ibrutinib in Combination With Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Actual Study Start Date : December 2015
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : August 2021
For enrollment please visit  
* The information provided by HTQ, HTQ employees, others appearing on the Site at the invitation of HTQ, or other visitors to the Site is NOT a medical advice.The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.